|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1638.70
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 50,737.50 | 50,962.10 | 44,660.70 | 59,482.20 | Total Expenditure | 38,664.30 | 37,192.80 | 35,173.10 | 35,875.70 | PBIDT (Excl OI) | 12,073.20 | 13,769.30 | 9,487.60 | 23,606.50 | Other Income | 2,284.80 | 1,159.30 | 1,635.40 | 1,203.00 | Operating Profit | 14,358.00 | 14,928.60 | 11,123.00 | 24,809.50 | Interest | 2,149.20 | 1,936.30 | 1,579.40 | 1,614.50 | Exceptional Items | -698.10 | 0 | -1,492.10 | -29,377.90 | PBDT | 11,510.70 | 12,992.30 | 8,051.50 | -6,182.90 | Depreciation | 3,996.00 | 3,927.10 | 4,152.70 | 4,119.80 | Profit Before Tax | 7,514.70 | 9,065.20 | 3,898.80 | -10,302.70 | Tax | 301.60 | 178.90 | 92.40 | -94.50 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 7,213.10 | 8,886.30 | 3,806.40 | -10,208.20 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 7,213.10 | 8,886.30 | 3,806.40 | -10,208.20 | Equity Capital | 2,399.30 | 2,399.30 | 2,399.30 | 2,399.30 | Face Value (IN RS) | 1 | 1 | 1 | 1 | Reserves | | | | | Calculated EPS | 3.01 | 3.70 | 1.59 | -4.25 | Calculated EPS (Annualised) | 12.03 | 14.81 | 6.35 | -17.02 | No of Public Share Holdings | 1,092,200,435.00 | 1,092,200,435.00 | 1,092,200,435.00 | 1,092,200,435.00 | % of Public Share Holdings | 45.52 | 45.52 | 45.52 | 45.51 | | | | | | PBIDTM% (Excl OI) | 23.80 | 27.02 | 21.24 | 39.69 | PBIDTM% | 28.30 | 29.29 | 24.91 | 41.71 | PBDTM% | 22.69 | 25.49 | 18.03 | -10.39 | PBTM% | 14.81 | 17.79 | 8.73 | -17.32 | PATM% | 14.22 | 17.44 | 8.52 | -17.16 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|